The debate over generic versus brand-name prescribing in India has moved firmly from policy aspiration to legal obligation. The National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023 — operative from 2023 — require all registered medical practitioners to prescribe medicines by their International Non-proprietary Name (INN), commonly known as the generic name. A prescription that only lists a brand name, with no INN, is now technically non-compliant with the professional conduct regulations that govern every MBBS doctor in India.

This article explains what the INN mandate actually requires, the history behind it, when brand names are permitted, what the Jan Aushadhi scheme means for patients, and how a doctor can write a compliant prescription without compromising clinical judgement.

"The generic prescribing mandate is sound public health policy — it reduces costs for patients and prevents pharmaceutical company influence over prescribing. But doctors need to understand exactly what is required of them legally, and what the consequences of non-compliance are, before they can make an informed choice about how to write their prescriptions."
— Dr. Namit Gupta, Senior Medico-Legal Expert

What Is the INN / Generic Name?

The International Non-proprietary Name (INN) is the globally recognised generic name of an active pharmaceutical ingredient, assigned by the World Health Organisation. It identifies the active substance without reference to the manufacturer or brand.

For example:

  • INN: PARACETAMOL — Brand names: Crocin, Calpol, Dolo, Tylenol (same molecule, different brands)
  • INN: AMOXICILLIN — Brand names: Mox, Novamox, Amoxil
  • INN: ATORVASTATIN — Brand names: Lipitor, Atorva, Aztor

A prescription written with the INN allows the pharmacist to dispense any bioequivalent generic product manufactured under that name, not just the specific brand the doctor might have had in mind. This is the core of the generic prescribing mandate.

The History: From MCI Code of Ethics 2002 to NMC Regulations 2023

The idea of generic prescribing in India is not new. Clause 1.5 of the MCI Code of Medical Ethics Regulations, 2002 already stated that practitioners should prescribe drugs with generic names wherever possible. However, the 2002 provision used the word "should" — making it aspirational rather than mandatory. It was also poorly enforced, and brand-name prescribing remained overwhelmingly dominant in Indian clinical practice.

In 2017, Prime Minister Narendra Modi publicly urged doctors to prescribe generic medicines, triggering a national conversation. The NMC Act, 2019, which replaced the MCI, included provisions for the NMC to regulate professional conduct more vigorously. The NMC RMP (Professional Conduct) Regulations, 2023 converted the aspiration into a clear professional obligation — using mandatory language that makes INN prescribing compulsory, not discretionary.

What the NMC 2023 Regulations Actually Say

The NMC Regulations 2023 require that:

  • Prescriptions must be written legibly in capital letters
  • The drug must be identified by its generic (INN) name
  • The prescription must state the dose, dosage form, frequency, and duration
  • The doctor's registration number must appear on every prescription
  • A brand name may be added in brackets after the INN if the doctor believes clinical reasons justify a specific brand — but the INN must still be the primary name

The Regulations also prohibit prescribing drugs that are not evidence-based or have no established efficacy for the indicated condition — a provision that overlaps with the principles of rational prescribing.

When Is Adding a Brand Name Permitted?

The NMC Regulations recognise that in some clinical situations, a doctor may have a legitimate reason to prefer a specific brand. This may arise where:

  • Bioequivalence of generic products is uncertain for narrow therapeutic index drugs (e.g., anticoagulants, anti-epileptics, immunosuppressants) and the patient is already stabilised on a specific brand
  • A particular formulation or delivery mechanism is only available from one manufacturer
  • The patient has a documented history of adverse reactions to excipients used by certain generic manufacturers

In these situations, the doctor can add the brand name in brackets — e.g., "WARFARIN 5 mg (Warf 5)" — with the INN written first in capital letters. The doctor's clinical reasoning should be documented in the case record.

The Jan Aushadhi Scheme and Jan Aushadhi Kendras

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), popularly known as the Jan Aushadhi scheme, is the government's flagship programme to make quality generic medicines available at significantly lower prices. Jan Aushadhi Kendras (JAKs) are government-supported pharmacy outlets that stock only generic medicines.

As of 2025, over 10,500 Jan Aushadhi Kendras operate across India, stocking more than 1,900 generic medicines. The scheme is the institutional mechanism through which the NMC's generic prescribing mandate is intended to benefit patients — a doctor who prescribes by INN enables the patient to purchase the medicine at a Jan Aushadhi Kendra at a fraction of the branded price.

For patients in rural and semi-urban India, access to Jan Aushadhi Kendras alongside generic prescribing can reduce out-of-pocket medicine expenditure by 50–90% for common chronic conditions such as diabetes, hypertension, and thyroid disorders.

Bioequivalence Concerns — The Doctor's Perspective

The most commonly raised objection by doctors to generic prescribing is bioequivalence uncertainty — the concern that Indian generic drugs, while containing the same active molecule, may differ in absorption, distribution, and clinical effect due to differences in manufacturing standards, excipients, or formulation.

This concern has some clinical legitimacy for a narrow category of drugs — particularly those with narrow therapeutic indices such as warfarin, digoxin, lithium, phenytoin, levothyroxine, and cyclosporine. For these drugs, small differences in bioavailability can translate to clinical differences, and regulatory agencies worldwide accept that patients stabilised on branded versions should generally continue on the same product.

However, for the vast majority of drugs in routine clinical use — antibiotics, antihypertensives, antidiabetics, statins — bioequivalence concerns are not clinically significant, and the NMC's mandate is appropriate. A doctor who refuses to prescribe generics for all drugs on the grounds of bioequivalence is not making a defensible clinical argument for most of those drugs.

Penalty for Non-Compliance

A doctor who consistently writes prescriptions with only brand names and no INN may face:

  • Notice from the NMC Ethics and Medical Registration Board (EMRB): The EMRB has the power to investigate professional misconduct complaints and to issue warnings, impose fines, or recommend suspension or cancellation of registration
  • Consumer forum complaints: A patient who believes they were prescribed an expensive branded drug when a cheaper generic was available and the doctor failed to mention it could file a consumer complaint for deficiency of service
  • Reputational risk: Given increased public and media awareness of the generic prescribing mandate, doctors who are seen to systematically prescribe brands without INN names face public criticism

Real NMC notices for generic prescribing violations have been issued since 2023, primarily through the state ethics body route, though the number reaching formal hearing stage remains relatively small. The trend, however, is clearly toward stricter enforcement.

A Compliant Prescription: Sample Format

The following is an example of a legally compliant prescription under the NMC 2023 Regulations:

Dr. [FULL NAME], MBBS, MD
Reg. No.: [State Medical Council Registration Number]
[Clinic Name and Address]
Date: [DD/MM/YYYY]

Patient: [Patient Full Name]       Age: [xx] years
Address: [Patient Address]

Rx

1. METFORMIN 500 MG (Glycomet) — 1 tab twice daily with meals
   Qty: 60 tablets

2. ATORVASTATIN 10 MG — 1 tab at bedtime
   Qty: 30 tablets

3. AMLODIPINE 5 MG — 1 tab once daily in the morning
   Qty: 30 tablets

Advice: [Diet / lifestyle / follow-up instructions]
Follow-up: [Date / review after X days/weeks]

Dr. [Name]
Signature & Seal

Key features of this prescription: drug names are in capital letters with the INN as the primary name; registration number is present; dose, form, frequency, and quantity are specified; a brand name is added in brackets only where the doctor has a clinical preference. Prescriptions written in this format are fully compliant with both the NMC 2023 Regulations and the Drugs and Cosmetics Act requirements.

Conclusion

The NMC generic prescribing mandate is not merely aspirational policy — it is an enforceable professional obligation. Doctors who write brand-name-only prescriptions routinely are exposed to professional misconduct proceedings before the NMC. The transition to INN prescribing is straightforward in practice: most prescription management software can be configured to show the INN by default, and the doctor retains full clinical discretion to add a preferred brand in brackets where genuinely warranted.

If you have received an NMC notice relating to prescribing practices, or need guidance on how to comply while protecting your clinical autonomy, contact our team for a confidential medico-legal consultation.